Cat.No. : CSC-RO0125 Host Cell: Ba/F3
Size: >1x10^6 frozen cells/vial, 1 mL Stability: Stable in culture over a minimum of 10 passages
| Cat. No. | CSC-RO0125 |
| Description | Ba/F3-BCR-ABL cell line is a stably transfected cell line which expresses human BCR-ABL fusion protein with T315I mutation in ABL. |
| Target Gene | BCR-ABL |
| Gene Species | Homo sapiens (Human) |
| Host Cell | Ba/F3 |
| Host Cell Species | Mus musculus (Mouse) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Growth Conditions | 37 °C, 5% CO2 |
| Quality Control | Negative for bacteria, yeast, fungi and mycoplasma. |
| Shipping | Dry ice |
| Size | >1x10^6 frozen cells/vial, 1 mL |
| Biosafety Level | 2 |
| Thawing & Subculturing Instructions | 1. Thaw cells by gently swirling in a 37°C water bath. To limit contamination, do not submerge the O-ring and cap. 2. When cells are ~70% thawed (~1 min), transfer the vial into a biosafety cabinet, and wipe the surface with 70% ethanol. Allow tube to dry completely. 3. Transfer the cells gently into a 15 mL conical tube containing 10 mL of pre-warmed culture medium (without antibiotic selection marker). Centrifuge cells at ~125 x g for 5~7 min. 4. Remove supernatant without disturbing the pellet, and resuspend cells in 1 mL culture medium (without antibiotic selection marker). Transfer cells to a 6-well plate containing ~2 mL pre-warmed growth medium (without antibiotic selection marker) or a T25 flask containing 5 mL pre-warmed culture medium (without antibiotic selection marker). 5. Incubate the culture at 37°C with 5% CO2. 6. Subculture: split saturated culture 1:4 ~ 1:6 every 3 days; seed out at about 1~3 x 10^5 cells/mL. |
| Growth Properties | Suspension, round |
| Freeze Medium | Frozen with 70% medium, 20% FBS, 10% DMSO |
| Freezing Instructions | Cells are recommended to generate additional frozen stocks at early passages. Frozen stocks should be preserved in a designated cryopreservation medium or in 70% RPMI 1640 + 20% FBS + 10% DMSO (without antibiotic selection marker). 1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO, without antibiotic selection marker) fresh immediately before use. 2. Keep the freezing medium on ice and label cryovials. 3. Transfer cells to a sterile, conical centrifuge tube, and count the cells. 4. Centrifuge the cells at 250 x g for 5 minutes at room temperature and carefully aspirate off the medium. 5. Resuspend the cells at a density of at least 3 x10^6 cells/ml in chilled freezing medium. 6. Aliquot 1 ml of the cell suspension into each cryovial. 7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer. 8. Transfer vials to liquid nitrogen for long-term storage. |
| Mycoplasma | Negative |
| Format | One frozen vial containing millions of cells |
| Storage | Liquid nitrogen |
| Safety Considerations |
The following safety precautions should be observed. 1. Use pipette aids to prevent ingestion and keep aerosols down to a minimum. 2. No eating, drinking or smoking while handling the stable line. 3. Wash hands after handling the stable line and before leaving the lab. 4. Decontaminate work surface with disinfectant or 70% ethanol before and after working with stable cells. 5. All waste should be considered hazardous. 6. Dispose of all liquid waste after each experiment and treat with bleach. |
| Ship | Dry ice |
The cAMP-responsive element binding protein (CREB) is a nuclear transcription factor vital for cell growth and regulation, and its overexpression is associated with myeloid leukemia. Researchers have demonstrated that CREB contributes significantly to hematopoietic stem cell (HSC) proliferation and myeloid leukemia progression. They employed RNA interference to knock down CREB expression, leading to decreased proliferation in both HSCs and myeloid leukemia cells. The use of Ba/F3 cells expressing either Bcr-Abl wild-type or the imatinib-resistant T315I mutation highlighted CREB's critical role in leukemogenesis, revealing that CREB knockdown resulted in significantly reduced leukemic infiltration in vivo and extended survival in mouse models.
Figure 1. The researchers utilized Western blot and lentiviral transduction methods to analyze CREB expression in Ba/F3 cells, demonstrating its role in inhibiting leukemia progression and improving survival. (Cheng JC, et al., 2008)
Creative Biogene offers a Human BCR-ABL-T315I Stable Cell Line-Ba/F3, tailored for studies in leukemia research, particularly those targeting Bcr-Abl-mediated signaling pathways. Our stable cell line serves as an invaluable tool for exploring the role of various genetic alterations and therapeutic responses in hematological malignancies.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
The emergence of the Human BCR-ABL-T315I Stable Cell Line Ba/F3 product has provided strong support for the study of BCR-ABL fusion proteins, allowing me to better explore the complex mechanisms behind them during experiments.
Through this product, we can quickly and accurately study the impact of T315I mutation on the function of BCR-ABL fusion protein, thereby better understanding the resistance mechanisms of CML and ALL.
Write a review of your use of Biogene products and services in your research. Your review can help your fellow researchers make informed purchasing decisions.
Our promise to you:
Guaranteed product quality, expert customer support.
24x7 CUSTOMER SERVICE
CONTACT US TO ORDER
Copyright © Creative Biogene. All rights reserved.
